Targeting B-cell receptor signaling: changing the paradigm.
11Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX.
Hematology. American Society of Hematology. Education Program
|December 10, 2013
Summary
New targeted therapies inhibiting the B-cell receptor (BCR) pathway show promise for B-cell malignancies. These oral agents are effective with mild toxicity, impacting future treatment strategies.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- B-cell receptor (BCR) signaling is crucial for normal B-cell development and survival.
- Aberrant BCR signaling promotes viability and therapeutic resistance in B-cell malignancies.
- Targeting key kinases in the BCR pathway presents a novel therapeutic strategy.
Purpose of the Study:
- To review the emerging role of BCR pathway inhibitors in treating B-cell malignancies.
- To summarize the clinical activity and toxicity profiles of these novel agents.
- To discuss future research directions, including combination therapies and resistance mechanisms.
Main Methods:
- Review of early clinical studies involving BCR pathway inhibitors.
- Analysis of treatment responses and toxicity in patients with B-cell lymphomas and chronic lymphocytic leukemia.
- Discussion of ongoing and future clinical trials.
Main Results:
- Oral agents targeting Bruton tyrosine kinase, PI3K, and spleen tyrosine kinase demonstrate significant activity in B-cell malignancies.
- Impressive responses observed in mantle cell lymphoma and chronic lymphocytic leukemia.
- Generally mild toxicity profiles with limited myelosuppression reported.
Conclusions:
- BCR pathway inhibitors are effective and well-tolerated, offering a new therapeutic option for B-cell cancers.
- These agents are poised to significantly influence future treatment paradigms for B-cell malignancies.
- Further research is needed to optimize combination regimens, identify biomarkers, and overcome resistance.
Related Concept Videos
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:15Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
01:26Signal Transduction: Overview
8.6K
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...
8.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
01:28Diversity of Antigen Receptors
2.1K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
2.1K
01:24B Cell Activation and Differentiation
14.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
14.4K